A study reported by prominent scientists that IPI 504, a potent HSP90 inhibitor, has shown therapeutic response in patients with NSCLC, especially those with anaplastic lymphoma kinase gene rearrangements [68]. Here, HSP90AA1 is linked to non-small cell lung carcinoma.